RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single ...
Management provided a 2026 adjusted total revenue target of $230 million to $270 million, including $35 million to $45 million of Nuvaxovid product sales under existing orders, $40 million to $50 ...
NORTHAMPTON, MA / ACCESS Newswire / April 28, 2026 / Direct Relief and The Pfizer Foundation today announced the third cohort of the Innovation Awards in Community Health, supporting infectious ...
Bristol Myers Squibb and Pfizer will sell their blockbuster blood thinner Eliquis through Mark Cuban's Cost Plus Drugs ...
Pfizer is selling its remaining stake in COVID-19 vaccine partner BioNTech. The U.S. drugmaker is offering about 4.55 million American depositary receipts in an overnight block trade, marketed at ...
The MarketWatch News Department was not involved in the creation of this content. Repertoire and Pioneering Medicines, Flagship's in-house drug development unit, will jointly conduct research ...
Pfizer Inc. (NYSE:PFE) ranks among the top picks for a retirement portfolio. BMO Capital reaffirmed its Outperform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on September 23 in response to ...
Pfizer (NYSE:PFE) is preparing multiple presentations for the upcoming ASCO conference that spotlight new data across its ...
Pfizer’s dividend yield has surged to 6.3% after a 55% share price drop since 2021, prompting concerns about its sustainability. Management has pledged to maintain the payout, but payout ratios above ...
AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net ...
Repertoire and Pioneering Medicines, Flagship's in-house drug development unit, will jointly conduct research activities leveraging Repertoire's DECODE™ platform CAMBRIDGE, Mass., Dec. 22, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results